Clinical Trials Browser

Bevacizumab × CNS × 90 days × Clear all

NCT07623577 2026-06-03

Sac-TMT Combined With Bevacizumab in TNBC With Brain Metastases

Phase 2 Recruiting

Brain Neoplasms

NCT01083966 2026-06-01

Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

Phase 1 Suspended

Brain Neoplasms, Neurilemmoma, Neuroma, Neuroma, Acoustic

NCT01269853 2026-06-01

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

Phase 1/2 Recruiting

Astrocytoma, Glioblastoma, Neoplasms

NCT01386710 2026-06-01

Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma

Phase 1/2 Suspended

Astrocytoma, Glioblastoma, Neoplasms

NCT05271240 2026-06-01

Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM

Phase 3 Recruiting

Brain Neoplasms, Glioblastoma, Glioma

NCT07346157 2026-06-01

PNOC044

Phase 1/2 Not yet recruiting

Medulloblastoma

NCT02971501 2026-05-29

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

5 enrolled 9 charts

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05919264 2026-05-28

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

CNSGastrointestinalGenitourinaryGynecologicSarcoma

Craniopharyngioma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Neoplasms, Adenomatous Polyposis Coli, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Desmoid Tumors

NCT06955169 2026-05-22

MOMENTUM-1

Phase 2 Suspended

Meningioma

NCT05871021 2026-05-18

PRIDE

Phase 2 Recruiting

Glioblastoma

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

Phase 1 Terminated

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT02308527 2026-05-12

BEACON

Phase 2 Completed

Neuroblastoma

NCT03554707 2026-05-08

SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Phase EARLY_PHASE1 Withdrawn

Central Nervous System Neoplasms

NCT04374305 2026-05-06

INTUITT-NF2

Phase 2 Recruiting

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

NCT02142803 2026-04-29

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors

Phase 1 Active not recruiting

50 enrolled 16 charts

Fallopian Tube Neoplasms, Glioblastoma, Ovarian Neoplasms

NCT07297212 2026-04-29

A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma

Phase 2 Recruiting

Brain Neoplasms, Glioblastoma

NCT07398599 2026-04-23

Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study

Phase NA Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT07541781 2026-04-21

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Phase 1 Not yet recruiting

Glioblastoma, Glioma

NCT03175432 2026-04-15

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04446416 2026-04-09

Efficacy and Safety of NaviFUS System add-on Bevacizumab (BEV) in Recurrent GBM Patients

Phase NA Completed

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06329570 2026-04-09

Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Phase 1/2 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT06496971 2026-04-09

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Phase 3 Recruiting

Brain Neoplasms, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue

NCT07481786 2026-04-06

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Phase 3 Recruiting

Adenocarcinoma of Lung, Brain Neoplasms

NCT06812871 2026-04-02

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Phase 2 Completed

Meningeal Carcinomatosis

NCT07449481 2026-04-01

A Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

Phase 2 Not yet recruiting

Brain Neoplasms

NCT01743950 2026-03-25

A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab

Phase 2 Terminated

49 enrolled 19 charts

Glioblastoma, Glioma